Remove Arrhythmia Remove Biomarkers Remove Reimbursement
article thumbnail

Cardiac Wire Q&A: ECG Automation’s Care Impact

CardiacWire

Jimenez and Ali co-founded AccurKardia in 2019 with a vision for unlocking the value of the ECG signal, and the company currently markets one of the few FDA-cleared solutions for automated ECG interpretation and arrhythmia detection. Here’s the rest of their story and vision for ECG automation.

article thumbnail

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

The cohort receiving the lowest dose of 20 million cells has been initiated with no treatment-emergent adverse events, arrhythmias, rejection, or allergic response. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement. The first author of the study is R.

article thumbnail

American Heart Month Puts Spotlight on Cardiovascular Disease and Stroke Statistics

DAIC

Elevated levels of two protein biomarkers that indicate heart damage were associated with undetected or symptomless cardiovascular disease in adults with Type 2 diabetes compared to those without Type 2 diabetes, according to new research published May 31, 2023, in the Journal of the American Heart Association, JAHA. .**